NCT06768931View on ClinicalTrials.gov

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

January 8, 2030

Study Completion Date

February 8, 2035

Conditions
Breast CancerTriple Negative Breast Cancer (TNBC)Early Stage Breast CancerImmunotherapyProbiotic
Interventions
OTHER

Biolosion (oral probiotic compound preparation)

Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.

Trial Locations (5)

510060

RECRUITING

Sun yat sen university cancer center, Guangzhou

523059

NOT_YET_RECRUITING

Dongguan People's Hospital, Dongguan

524002

NOT_YET_RECRUITING

Central Hospital of Guangdong Nongken, Zhanjiang

643000

NOT_YET_RECRUITING

Zigong Fourth People's hospital, Zigong

730050

NOT_YET_RECRUITING

Gansu Cancer Hospital, Lanzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER